• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Unproven (Off-Label) Treatments

Unproven (Off-Label) Treatments

Background

Given the lack of approved and effective treatments for ALS, people diagnosed with the disease may seek out options that are not offered by their physician. Determining the difference between true and false information regarding ALS treatments can be difficult.

The internet has many websites that promote effective ALS treatments for purchase. Often they are well designed, boast treatments available for multiple diseases and ailments, and provide reassurance through online testimonials from previous clients. In nearly all of these cases, there is no evidence of safety and in all of them; there is no proof of benefit. Furthermore, these treatments are often extremely expensive, capitalizing on desperation and hope, and many people with ALS spend critical life savings or raise funds through family and friends for an opportunity to save their life.

Examples of such treatments include, but are not limited to; stem cell clinics, holistic/naturopathic/homeopathic/traditional medicine, and dietary or physical therapy regimens.

Resources like ALSUntangled (www.alsuntangled.com) can be valuable for balanced, open-access information about such alternative treatments and www.clinicaltrials.gov is a resource for determining whether a particular treatment is being tested in a legitimate clinical trial.

A forthcoming ALSUntangled podcast/review entitled ‘“ten red flags”-things to be wary of in alternative or off-label products’ provides helpful guide to the warning signs to look out for in an advertised potential treatment. Click here for the “ten red flags” article.

Recommendation

The SAC recommends that Alliance members defer all medical advice regarding unapproved/unproven/off-label treatments to an individual’s own clinician. This may be accompanied by objective information about the specific treatment, which may be provided by the SAC. Providing links to resources like ALSUntangled and clinical trials databases like www.clinicaltrials.gov are encouraged. Accompanying information can be especially important in situations where an individual does not have access to an ALS specialist physician and it may assist their clinician in making a medical recommendation. It can also be important to relay that there are thousands of researchers around the world who are dedicated to understanding ALS and finding effective treatments, and if there was anything, anywhere, that actually worked, we would know and we would do everything we could to get it to people living with the disease as soon as possible.

 

International Alliance of ALS/MND Associations
June 2020

 


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Advocacy

  • Advocacy Toolkit

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Gisli Jonasson, Iceland

    Gisli Jonasson, Iceland

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Shaleen Latchman, Canada

    Shaleen Latchman, Canada

  • Juvenal Bayona Romero, Colombia

    Juvenal Bayona Romero, Colombia

  • Camilla Heiberg Freiberg, Denmark

    Camilla Heiberg Freiberg, Denmark

  • Zelina Brito, Brazil

    Zelina Brito, Brazil

  • John Russo, USA

    John Russo, USA
    final3878

  • Alex, Argentina

    Alex, Argentina

  • Jon Newsome, USA

    Jon Newsome, USA

  • Osiel Mendoza, USA

    Osiel Mendoza, USA

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Federica Mastrosimone, Italy

    Federica Mastrosimone, Italy

  • Joanne Pratt, Australia

    Joanne Pratt, Australia

  • Diana Fernandez, Argentina

    Diana Fernandez, Argentina

  • John Sweeney, USA

    John Sweeney, USA

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

  • Margarita Pizarro, Argentina

    Margarita Pizarro, Argentina

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Lin Yong Yi, Taiwan

    Lin Yong Yi, Taiwan

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Carlos Alberto Báez Murillo, Colombia

    Carlos Alberto Báez Murillo, Colombia

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Colm Francis Davis, Ireland

    Colm Francis Davis, Ireland

  • Margreth Burger-Saile, Switzerland

    Margreth Burger-Saile, Switzerland

  • Jason Goodman, USA

    Jason Goodman, USA

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Mona H. Bahus and Camilla Knoff Glomstad, Norway

    Mona H. Bahus and Camilla Knoff Glomstad, Norway

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Greg Heydet, USA

    Greg Heydet, USA

  • Torben Mikkelsen, Denmark

    Torben Mikkelsen, Denmark

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Mauricio Dorin, Argentina

    Mauricio Dorin, Argentina

  • Kris Van Reusel, Belgium

    Kris Van Reusel, Belgium

  • Armando González Gómez, Colombia

    Armando González Gómez, Colombia

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • Steve

    Steve

  • Kirsten Harley, Australia

    Kirsten Harley, Australia

  • Semra Gokalp, Turkey

    Semra Gokalp, Turkey

  • Guido De Mets, Belgium

    Guido De Mets, Belgium

  • Seckin McGuirk, England

    Seckin McGuirk, England

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login